You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II (PD40)1 Sep 2021PD40-09 ASSOCIATION BETWEEN PRIOR NEPHRECTOMY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN METASTATIC RENAL CELL CARCINOMA - A SYSTEMATIC REVIEW AND META-ANALYSIS Raj Satkunasivam, Jonathan Christopher Guzman, Zachary Klaassen, Mary Hall, Amy Luckenbaugh, Aaron Laviana, Antonio DeRosa, Kathrynn Beckermann, Brian Rini, and Christopher J.D. Wallis Raj SatkunasivamRaj Satkunasivam More articles by this author , Jonathan Christopher GuzmanJonathan Christopher Guzman More articles by this author , Zachary KlaassenZachary Klaassen More articles by this author , Mary HallMary Hall More articles by this author , Amy LuckenbaughAmy Luckenbaugh More articles by this author , Aaron LavianaAaron Laviana More articles by this author , Antonio DeRosaAntonio DeRosa More articles by this author , Kathrynn BeckermannKathrynn Beckermann More articles by this author , Brian RiniBrian Rini More articles by this author , and Christopher J.D. WallisChristopher J.D. Wallis More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002050.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Immune checkpoint-inhibitor (ICI)-based therapy is the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC). It is unclear whether prior removal of the primary tumor influences the efficacy of these treatments. We performed a systematic review and meta-analysis of studies of first-line ICI in mRCC to determine whether the efficacy of ICI-therapy, compared to sunitinib, is altered based on receipt of prior nephrectomy. METHODS: We systematically reviewed studies indexed in MEDLINE (PubMed), Embase, and Scopus and conference abstracts from relevant medical societies as of August 2020 to identify randomized clinical trials assessing first-line immunotherapy-based regimes in mRCC. Studies were included if overall survival (OS) and progression-free survival (PFS) outcomes were reported with data stratified by nephrectomy status. We pooled hazard ratios (HRs) stratified by nephrectomy status and performed random effects meta-analysis to assess the null hypothesis of no difference in the survival advantage of immunotherapy-based regimes based on nephrectomy status, while accounting for study level correlations. RESULTS: Among 6 randomized clinical trials involving 5,121 patients, 3,968 (77%) had undergone prior nephrectomy. We found an overall survival benefit for immunotherapy-based regimes, compared to sunitinib, among both patients who had undergone nephrectomy (HR 0.75, 95% CI 0.63-0.88) and those who had not (HR 0.74, 95% CI 0.59-0.92), without evidence of difference based on nephrectomy history (p=0.70; I2=36%). Results assessing PFS were similar (p=0.45, I2=0%). CONCLUSIONS: These clinical data suggest that prior nephrectomy does not affect the efficacy of ICI-based regimens in mRCC relative to sunitinib. Source of Funding: Internal © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e677-e677 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Raj Satkunasivam More articles by this author Jonathan Christopher Guzman More articles by this author Zachary Klaassen More articles by this author Mary Hall More articles by this author Amy Luckenbaugh More articles by this author Aaron Laviana More articles by this author Antonio DeRosa More articles by this author Kathrynn Beckermann More articles by this author Brian Rini More articles by this author Christopher J.D. Wallis More articles by this author Expand All Advertisement Loading ...